Endocrine therapies, including the selective ER modulator (SERM), tamoxifen and the selective ER degrader (SERD), fulvestrant have been the mainstay therapy for the treatment of both early and late-stage ER+ breast cancer for decades. The gene discussed is ESR1; the disease is breast carcinoma.